Related Experiment Video
Updated: Feb 9, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
Apatinib as targeted therapy for sarcoma
Feng Li1,2,3,4, Zhichao Liao1,2,3,4, Chao Zhang1,2,3,4
1Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, People's Republic of China.
Abstract:
Sarcomas are a group of malignant tumors originating from mesenchymal tissue with a variety of cell subtypes. Despite several major treatment breakthroughs, standard treatment using surgery, radiation, and chemotherapy has failed to improve overall survival. Therefore, there is an urgent need to explore new strategies and innovative therapies to further improve the survival rates of patients with sarcomas. Pathological angiogenesis has an important role in the growth and metastasis of tumors. Vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFRs) play a central role in tumor angiogenesis and represent potential targets for anticancer therapy. As a novel targeted therapy, especially with regard to angiogenesis, apatinib is a new type of small molecule tyrosine kinase inhibitor that selectively targets VEGFR-2 and has shown encouraging anticancer activity in a wide range of malignancies, including gastric cancer, non-small cell lung cancer, breast cancer, hepatocellular carcinoma, and sarcomas. In this review, we summarize the preclinical and clinical data for apatinib, focusing primarily on its use in the treatment of sarcomas.
Insights
Apatinib, a targeted therapy inhibiting vascular endothelial growth factor receptor-2, shows promise for treating sarcomas. This review summarizes preclinical and clinical data on apatinib
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Sarcomas are malignant tumors of mesenchymal origin with limited survival improvements from standard treatments.
- Pathological angiogenesis is crucial for sarcoma growth and metastasis.
- Vascular Endothelial Growth Factor (VEGF) and its receptors (VEGFRs) are key regulators of tumor angiogenesis.
Purpose of the Study:
- To review preclinical and clinical data on apatinib for sarcoma treatment.
- To highlight apatinib as a novel targeted therapy for angiogenesis.
- To assess the potential of apatinib in improving sarcoma patient survival.
Main Methods:
- Review of preclinical studies on apatinib's anti-angiogenic and anti-tumor effects.
- Analysis of clinical trial data evaluating apatinib in various malignancies, including sarcomas.
- Focus on apatinib's selective inhibition of VEGFR-2.
Main Results:
- Apatinib demonstrates encouraging anticancer activity across multiple cancer types.
- Preclinical and clinical data suggest apatinib's efficacy in sarcoma treatment.
- Apatinib's targeted inhibition of VEGFR-2 impacts tumor angiogenesis.
Conclusions:
- Apatinib is a promising targeted therapy for sarcomas.
- Further investigation into apatinib's role in sarcoma treatment is warranted.
- Targeting angiogenesis with apatinib may improve outcomes for sarcoma patients.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Gene Therapy
Group Therapy
Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
Drug Therapy
Antianxiety Medications

